Woodline Partners’s Vaxcyte PCVX Stock Holding History
Bought
Maintained
Sold
Other funds holding PCVX
JT
RCM
DTC
Woodline Partners's PCVX Position: Q2 2026 in Review
Woodline Partners held its Vaxcyte (PCVX) position steady in Q2 2026 at 274,740 shares worth $16M. The position accounts for 0.05% of the portfolio, ranked #416.
Woodline Partners first reported a position in PCVX in Q2 2020 and has held it in 19 quarters since. The position peaked at $126M in Q3 2024. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.
- Woodline Partners held 274,740 shares of Vaxcyte worth $16M as of Q2 2026.
- Woodline Partners left its Vaxcyte share count unchanged in Q2 2026.
- Vaxcyte made up 0.05% of Woodline Partners's portfolio in Q2 2026, its #416 holding.
- Woodline Partners first reported a position in Vaxcyte in Q2 2020 and has held it in 19 quarters since.
- Woodline Partners's Vaxcyte position peaked at $126M in Q3 2024.
- 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.
Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.